US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
イギリス
LSE
Hyloris Pharmaceuticals Sa (0AB6)
Hyloris Pharmaceuticals Sa (0AB6) ニュース

0AB6

Hyloris Pharmaceuticals (0AB6)

Hyloris Pharmaceuticals Sa

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0AB6

1

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/14	15 : 00	UK Regulatory	Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/14	15 : 00	UK Regulatory	Hyloris Reports Full Year Results for 2023 & Provides Business Outlook	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/14	14 : 59	UK Regulatory	Communication at the request of the FSMA on the transactions with Qliniq	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/14	14 : 59	UK Regulatory	Communiqué à la requête de la FSMA sur les transactions avec QliniQ	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/08	15 : 00	UK Regulatory	Hyloris to Report 2023 Full-Year Results on 14 March 2024	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/08	15 : 00	UK Regulatory	Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/28	02 : 00	UK Regulatory	Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/28	02 : 00	UK Regulatory	Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/15	02 : 00	UK Regulatory	Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/15	02 : 00	UK Regulatory	Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/01/30	15 : 00	UK Regulatory	Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/01/30	15 : 00	UK Regulatory	Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)	LSE:0AB6	Hyloris Pharmaceuticals Sa

Showing the most relevant articles for your search:LSE:0AB6

1

SNCF Reseau Bond Matures...

Max Airlines -3x Inverse...

Incannex Healthcare

Eden Innovations

iShares MSCI Emerging Ma...

Pelican Resources

BANCO NORDESTE ON

Electro Optic Systems

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約